HK1253315A1 - 抗腫瘤組合物 - Google Patents

抗腫瘤組合物

Info

Publication number
HK1253315A1
HK1253315A1 HK18112608.9A HK18112608A HK1253315A1 HK 1253315 A1 HK1253315 A1 HK 1253315A1 HK 18112608 A HK18112608 A HK 18112608A HK 1253315 A1 HK1253315 A1 HK 1253315A1
Authority
HK
Hong Kong
Prior art keywords
tumoral
composition
tumoral composition
Prior art date
Application number
HK18112608.9A
Other languages
English (en)
Inventor
Limacher Jean-Marc
Original Assignee
Jean Marc Limacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jean Marc Limacher filed Critical Jean Marc Limacher
Publication of HK1253315A1 publication Critical patent/HK1253315A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18112608.9A 2015-10-08 2018-10-02 抗腫瘤組合物 HK1253315A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1559589A FR3042121A1 (fr) 2015-10-08 2015-10-08 Composition anti-tumorale
FR1659450A FR3042122B1 (fr) 2015-10-08 2016-09-30 Composition anti-tumorale

Publications (1)

Publication Number Publication Date
HK1253315A1 true HK1253315A1 (zh) 2019-06-14

Family

ID=55178130

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112608.9A HK1253315A1 (zh) 2015-10-08 2018-10-02 抗腫瘤組合物

Country Status (14)

Country Link
US (2) US20180296653A1 (zh)
EP (1) EP3359185B1 (zh)
JP (1) JP7211815B2 (zh)
KR (1) KR20180059547A (zh)
CN (1) CN108348587A (zh)
CA (1) CA2999948C (zh)
DK (1) DK3359185T3 (zh)
ES (1) ES2919134T3 (zh)
FR (2) FR3042121A1 (zh)
HK (1) HK1253315A1 (zh)
IL (1) IL258430B (zh)
LT (1) LT3359185T (zh)
RU (1) RU2728748C2 (zh)
WO (1) WO2017060650A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CN116676324B (zh) * 2023-07-28 2023-10-27 四川大学华西医院 基于Kil蛋白构建释放抗肿瘤效应蛋白的系统及方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
WO1998013500A2 (en) 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
EP1021545A2 (en) 1997-09-23 2000-07-26 Bavarian Nordic Research Institute A/S Dengue virus antigens and treatment of dengue fever
CA2397675C (en) 2000-03-14 2012-11-13 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)
EP1598425A1 (en) 2000-11-23 2005-11-23 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
UA82466C2 (uk) 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
EP1456230A2 (en) 2001-12-04 2004-09-15 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
IL161590A0 (en) 2001-12-10 2004-09-27 Bavarian Nordic As Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
ES2247404T3 (es) 2001-12-20 2006-03-01 Bavarian Nordic A/S Metodo para la recuperacion y purificacion de poxvirus de celulas infectadas.
DE60314823T3 (de) 2002-04-19 2017-11-16 Bavarian Nordic A/S Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
KR101196178B1 (ko) 2002-05-16 2012-11-01 버베리안 노딕 에이/에스 Ｈｉｖ 조절/부속 단백질의 융합 단백질
JP2005525821A (ja) 2002-05-16 2005-09-02 バヴァリアン・ノルディック・アクティーゼルスカブ 牛痘ａｔｉプロモーターを用いた変異ワクシニアウイルスアンカラ中の遺伝子の発現
EA012160B1 (ru) 2002-05-16 2009-08-28 Бавариан Нордик А/С Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном, и его применение
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
JP2006506991A (ja) 2002-11-25 2006-03-02 デン・コンゲリエ・ヴェテリネー−オ・ランボホイスコレ ブタ多型およびその検出のための方法
DE60314541T2 (de) 2002-11-25 2008-02-28 Bavarian Nordic A/S Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
AU2004230328A1 (en) * 2003-04-15 2004-10-28 Sanofi Pasteur Limited Tumor antigens BFA5 for prevention and/or treatment of cancer
DE602004027767D1 (de) 2003-11-24 2010-07-29 Bavarian Nordic As Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
BRPI0608310A2 (pt) 2005-02-23 2009-12-08 Bavarian Nordic As uso de um poxvìrus modificado para a indução rápida de imunidade contra um poxvìrus ou outros agentes infecciosos
US20100011451A1 (en) 2006-09-08 2010-01-14 Paul Chaplin Phenotypic and genotypic differences of mva strains
PT2073837E (pt) 2006-10-06 2014-09-22 Bavarian Nordic Inc Vírus vaccinia ankara modificado recombinante que codifica um antigénio her-2 em associação com um taxano para utilização no tratamento de cancro
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
NZ578959A (en) 2007-04-27 2012-12-21 Bavarian Nordic As Induction of dendritic cell development with macrophage-colony stimulating factor (m-csf)
AU2008250596C1 (en) 2007-05-14 2010-11-25 Bavarian Nordic A/S Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines
ES2608604T3 (es) 2007-10-18 2017-04-12 Bavarian Nordic A/S Uso de MVA para tratar el cáncer de próstata
US20110268744A1 (en) * 2008-05-26 2011-11-03 Ian Garthwaite Method of Diagnosis of Infection by Mycobacteria and Reagents Therefor
US20110052627A1 (en) 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
NZ602322A (en) 2008-11-21 2013-12-20 Bavarian Nordic As Vector comprising multiple homologous nucleotide sequences
CA2741724C (en) 2008-11-27 2016-10-04 Bavarian Nordic A/S Promoters for recombinant viral expression
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
EP2486138A1 (en) 2009-10-08 2012-08-15 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
CA2786333C (en) 2010-01-28 2018-03-20 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of mva
JP5945270B2 (ja) 2010-07-20 2016-07-05 バヴァリアン・ノルディック・アクティーゼルスカブ 発現産物を採取するための方法
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
AU2011316164B2 (en) 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
CA2815727C (en) 2010-11-05 2019-09-10 Bavarian Nordic A/S Modulation of immune responses by the poxviral k4 protein
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2864487B1 (en) 2012-06-22 2018-12-05 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
KR102435054B1 (ko) 2012-08-01 2022-08-22 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
WO2014037124A1 (en) 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
JP2016502507A (ja) 2012-10-19 2016-01-28 バヴァリアン・ノルディック・インコーポレイテッド 癌治療のための組成物および方法
SI2912183T1 (sl) 2012-10-28 2020-07-31 Bavarian Nordic A/S Promotor Pr13.5 za odzive robustne T-celice in protiteles
US9402888B2 (en) * 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
US20160271239A1 (en) * 2013-11-05 2016-09-22 Bavarian Nordic A/S Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
CN106456724A (zh) * 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
KR20180006916A (ko) * 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도

Also Published As

Publication number Publication date
FR3042121A1 (fr) 2017-04-14
ES2919134T3 (es) 2022-07-22
EP3359185B1 (fr) 2022-04-06
IL258430B (en) 2022-03-01
CA2999948C (fr) 2024-04-23
IL258430A (en) 2018-06-28
RU2018115534A3 (zh) 2020-02-26
RU2728748C2 (ru) 2020-07-31
JP7211815B2 (ja) 2023-01-24
WO2017060650A1 (fr) 2017-04-13
FR3042122B1 (fr) 2020-01-17
DK3359185T3 (da) 2022-07-04
KR20180059547A (ko) 2018-06-04
CA2999948A1 (fr) 2017-04-13
US20180296653A1 (en) 2018-10-18
RU2018115534A (ru) 2019-11-08
FR3042122A1 (fr) 2017-04-14
US20210138053A1 (en) 2021-05-13
LT3359185T (lt) 2022-06-27
CN108348587A (zh) 2018-07-31
JP2018531238A (ja) 2018-10-25
EP3359185A1 (fr) 2018-08-15

Similar Documents

Publication Publication Date Title
GB201512030D0 (en) Composition
GB201505527D0 (en) Composition
GB201521507D0 (en) Composition
GB201506827D0 (en) Composition
GB201515640D0 (en) Composition
GB201506830D0 (en) Composition
GB201506829D0 (en) Composition
GB201506825D0 (en) Composition
GB2545773B (en) Composition
GB201522603D0 (en) Composition
GB201506828D0 (en) Composition
HK1253315A1 (zh) 抗腫瘤組合物
GB201518348D0 (en) Composition
GB201514585D0 (en) Composition
GB201511697D0 (en) Composition
GB201509044D0 (en) Composition
GB201505520D0 (en) Composition
GB201504665D0 (en) Composition
GB201504307D0 (en) Composition
GB201522681D0 (en) Composition
GB201519327D0 (en) Composition
GB2537648B (en) Composition
GB201515639D0 (en) Composition
GB201508722D0 (en) Composition
GB201521384D0 (en) Composition